Because targeted therapy has substantially improved outcomes for patients with advanced diagnosis NSCLC, we focused our analysis on NSCLC patients who did not have known or likely driver mutations in EGFR, ALK, ROS1 or BRAF, which nevertheless are mutually exclusive with SMARCA4 alterations. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.